**Supplementary Table 1.** Serum levels ofCA-125 and soluble CD23 and pain scores up to 24 months of follow-up after device placement, according to treatment: intention-to-treat analysis.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | ENG implant (*n*=52) |  | 52 mg LNG-IUS (*n*=51) | *p-*valuea |
| Mean±SEM | Range | 95% CI | CV |  | Mean±SEM | Range | 95% CI | CV |
| CA-125 |  |  |  |  |  |  |  |  |  |  |
|  Baseline | 39.1±7.8 (*n*=52) | 3.1-269.7 | 23.4, 54.8 | 142.5 |  | 26.0±4.4 (*n*=51) | 2.8-176.2 | 17.2, 34.9 | 119.5 | 0.539 |
|  6 months | 25.5±5.1 (*n*=43) | 2.2-227.0 | 15.3, 35.8 | 142.1 |  | 22.1±4.3 (*n*=39) | 3.0-183.8 | 15.3, 32.8 | 128.0 | 0.852 |
|  12 months | 24.8±5.0 (*n*=13) | 2.1-227 | 14.6, 35.0 | 146.0 |  | 22.1±4.4 (*n*=23) | 2.5-183.8 | 16.1, 34.1 | 125.4 | 0.847 |
|  18 months | 22.6±3.6 (*n*=20) | 2.1-121.3 | 15.2, 29.9 | 116.1 |  | 25.1±4.3 (*n*=22) | 2.5-183.8 | 16.2, 33.9 | 123.7 | 0.320 |
|  24 months | 24.0±6.1 (*n*=18) | 2.1-301.8 | 11.6, 36.4 | 183.2 |  | 28.6±4.9 (*n*=19) | 2.5-183.8 | 18.7, 39.4 | 121.2 | 0.111 |
| Soluble CD23 |  |  |  |  |  |  |  |  |  |  |
|  Baseline | 45.8±15.3 (*n*=52) | 1-604.8 | 15.0, 76.6 | 238.9 |  | 29.0±9.2 (*n*=51) | 1-397.5 | 10.4, 47.6 | 223.1 | 0.736 |
|  6 months | 6.4±1.6 (*n*=43) | 1-6.3 | 3.1, 9.7 | 180.0 |  | 8.8±2.5 (*n*=39) | 1-91 | 3.7, 13.9 | 202.1 | 0.421 |
|  12 months | 5.0±1.3 (*n*=13) | 0.6-61.3 | 2.2, 7.8 | 194.0 |  | 7.6±2.5 (*n*=23) | 0.69-9 | 2.4, 12.7 | 236.0 | 0.590 |
|  18 months | 3.0±0.6 (*n*=20) | 0.7-24.6 | 1.7, 4.3 | 149.8 |  | 7.3±2.5 (*n*=22) | 0.69-9 | 2.1, 12.4 | 246.3 | 0.529 |
|  24 months | 3.2±0.6 (*n*=18) | 0.6-24.6 | 1.9, 4.5 | 142.2 |  | 7.2±2.5 (*n*=19) | 0.93-9 | 2.1, 12.4 | 246.8 | 0.363 |
| VAS score for chronic pelvic pain |  |  |  |  |  |  |  |  |  |  |
|  Baseline | 7.5±0.2 (*n*=52) | 4-10 | 7.1, 8.0 | 21.8 |  | 7.4±0.2 (*n*=51) | 4-10 | 6.9, 7.9 | 236.1 | 0.587 |
|  6 months | 3.2±0.4 (*n*=43) | 0-10 | 2.2, 4.2 | 1.0 |  | 3.4±0.4 (*n*=39) | 0-10 | 2.4, 4.4 | 104.3 | 0.719 |
|  12 months | 3.3±0.4 (*n*=13) | 0-10 | 2.3, 4.3 | 102.6 |  | 4.4±0.4 (*n*=23) | 0-10 | 3.4, 5.4 | 79.4 | 0.081 |
|  18 months | 3.6±0.9 (*n*=20) | 0-10 | 2.7, 4.6 | 91.8 |  | 4.0±0.5 (*n*=22) | 0-10 | 2.9, 5.1 | 94.8 | 0.601 |
|  24 months | 3.4±0.4 (*n*=18) | 0-10 | 2.4, 4.4 | 99.7 |  | 4.2±0.5 (*n*=19) | 0-10 | 3.2, 5.3 | 87.4 | 0.211 |
| VAS score for dysmenorrhoea |  |  |  |  |  |  |  |  |  |  |
|  Baseline | 7.5±0.1 (*n*=52) | 4-10 | 7.1, 8.0 | 218.9 |  | 7.4±0.2 (*n*=51) | 4-10 | 6.9, 7.9 | 23.6 | 0.587 |
|  6 months | 3.3±0.5 (*n*=43) | 0-10 | 2.3, 4.4 | 109.4 |  | 3.4±0.4 (*n*=39) | 0-10 | 2.5, 4.4 | 98.5 | 0.541 |
|  12 months | 3.6±0.5 (*n*=13) | 0-10 | 2.6, 4.6 | 100.2 |  | 4.2±0.5 (*n*=23) | 0-10 | 3.1, 5.2 | 88.5 | 0.341 |
|  18 months | 3.7±0.5 (*n*=20) | 0-10 | 2.7, 4.7 | 98.3 |  | 4.0±0.5 (*n*=22) | 0-10 | 3.3, 5.4 | 90.5 | 0.644 |
|  24 months | 4.3±0.4 (*n*=18) | 0-10 | 3.3, 5.2 | 82.3 |  | 4.4±0.5 (*n*=19) | 0-10 | 17.2, 34.9 | 82.9 | 0.881 |

aMann–Whitney *U* test.

CV, coefficient of variation.